Strs Ohio Sells 46,600 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Strs Ohio trimmed its stake in Bristol Myers Squibb by 8.0%, selling 46,600 shares and ending the quarter with 532,622 shares valued at about $28.73 million.
• BMY beat Q1 expectations with $1.58 EPS and $11.49B revenue and management reiterated FY‑2026 guidance, while late‑stage pipeline catalysts (milvexian, Cobenfy) are balanced by the multi‑billion Eliquis patent cliff and a consensus analyst target near $61.31.
• Dividend and market context — the company pays a $0.63 quarterly dividend (4.3% yield, 73% payout ratio), shares traded near $58.24 and were down ~3.9% after the quarter, with institutional ownership around 76%.

Strs Ohio cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 532,622 shares of the biopharmaceutical company's stock after selling 46,600 shares during the quarter. Strs Ohio's holdings in Bristol Myers Squibb were worth $28,730,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of BMY. Vanguard Group Inc. grew its stake in Bristol Myers Squibb by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock worth $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. State Street Corp lifted its stake in Bristol Myers Squibb by 2.0% in the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after buying an additional 1,855,238 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Bristol Myers Squibb by 11.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock worth $818,105,000 after buying an additional 1,873,618 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Bristol Myers Squibb by 8.4% during the 3rd quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company's stock worth $770,116,000 after buying an additional 1,317,199 shares in the last quarter. Finally, Pzena Investment Management LLC grew its position in shares of Bristol Myers Squibb by 0.4% during the 3rd quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company's stock worth $672,062,000 after buying an additional 58,129 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
• Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1
• Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company NYSE: BMY Receives $61.31 Consensus PT from Analysts
• Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Bristol Myers Squibb Stock Down 3.9%

BMY opened at $58.24 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market capitalization of $118.92 billion, a P/E ratio of 16.36, a PEG ratio of 0.17 and a beta of 0.26. The company's 50-day moving average is $59.56 and its 200 day moving average is $54.55. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 66.57%. The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the business posted $1.80 EPS. The company's revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.29 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BMY. Wells Fargo & Company reiterated an "outperform" rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a "hold" rating in a report on Tuesday, March 17th. Morgan Stanley reiterated an "underweight" rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a research report on Friday. Finally, Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $61.31.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.05% of the company's stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.